Organization
Department of Pulmonary Diseases, Erasmus MC, Rotterdam, Netherlands
2 abstracts
Abstract
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.Org: Department of Pulmonary Diseases, Erasmus MC, Rotterdam, Netherlands, Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain, Clinical Research Unit, Military Hospital Begin, Saint-Mandé, France, Hopital Morvan CHU de Brest, Brest, France, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland,
Abstract
Analysis of significant weight gain in patients using alectinib for ALK-positive lung cancer.Org: Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Erasmus MC University Medical Center, Erasmus Medical Center, Erasmus MC Kankerinstituut, Department of Pulmonary Medicine,